2023 Taiwan Society of Cardiology (TSOC) and Taiwan College of Rheumatology (TCR) Joint Consensus on Connective Tissue Disease-Associated Pulmonary Arterial Hypertension
Journal
Acta Cardiologica Sinica
Journal Volume
39
Journal Issue
2
Pages
213–241
Date Issued
2023-03
Author(s)
Huang, Wei-Chun
Hsieh, Tsu-Yi
Wu, Yih-Jer
Charng, Min-Ji
Chen, Wei-Sheng
Sung, Shih-Hsien
Tsao, Yen-Po
Ho, Wan-Jing
Lai, Chien-Chih
Cheng, Chin-Chang
Tsai, Hung-Cheng
Hsu, Chih-Hsin
Chiu, Yu-Wei
Shen, Chieh-Yu
Wu, Chun-Hsien
Liu, Feng-Cheng
Yeh, Fu-Chiang
Liu, Wei-Shin
Lee, Hui-Ting
Wu, Shu-Hao
Chang, Chi-Ching
Chu, Chun-Yuan
Hou, Charles Jia-Yin
Tsai, Chang-Youh
Abstract
Pulmonary arterial hypertension (PAH), defined as the presence of a mean pulmonary artery pressure > 20 mmHg, pulmonary artery wedge pressure ≤ 15 mmHg, and pulmonary vascular resistance (PVR) > 2 Wood units based on expert consensus, is characterized by a progressive and sustained increase in PVR, which may lead to right heart failure and death. PAH is a well-known complication of connective tissue diseases (CTDs), such as systemic sclerosis, systemic lupus erythematosus, Sjogren's syndrome, and other autoimmune conditions. In the past few years, tremendous progress in the understanding of PAH pathogenesis has been made, with various novel diagnostic and screening methods for the early detection of PAH proposed worldwide.
Subjects
Connective tissue diseases; Pulmonary arterial hypertension; Sjogren’s syndrome; Systemic lupus erythematosus; Systemic sclerosis
SDGs
Type
journal article